GSE128099 GSE128159 gemcitabine SUM159PT 3 v 2 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE128099_GSE128159_gemcitabine_SUM159PT_3_v_2_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE128099_GSE128159_gemcitabine_SUM159PT_3_v_2_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE128099_GSE128159_gemcitabine_SUM159PT_3_v_2_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE128099_GSE128159_gemcitabine_SUM159PT_3_v_2_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

MAGE family member A3

Gene

keratin 7

Gene

eukaryotic translation initiation factor 5A

Gene

MAGE family member A6

Gene

brain expressed X-linked 1

Gene

alpha-2-glycoprotein 1, zinc-binding

Gene

toll like receptor 4

Gene

asparagine synthetase (glutamine-hydrolyzing)

Gene

brain abundant membrane attached signal protein 1

Gene

monoglyceride lipase

  • Gene

    MAGE family member A3



  • Gene

    eukaryotic translation initiation factor 5A


  • Gene

    MAGE family member A6


  • Gene

    brain expressed X-linked 1


  • Gene

    alpha-2-glycoprotein 1, zinc-binding


  • Gene

    toll like receptor 4


  • Gene

    asparagine synthetase (glutamine-hydrolyzing)


  • Gene

    brain abundant membrane attached signal protein 1


  • Gene

    monoglyceride lipase

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.